Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

Authors: Nargiz Majidova, Hacı Arak, Faruk Recep Ozalp, Onur Bas, Gulhan Ozcelik Koker, Erkan Buket Ozmarasalı, Yasemin Sagdıc Karateke, Teoman Sakalar, Sendag Yaslikaya, Ilknur Deliktas Onur, Goncagul Akdag, Ali Ogul, Murad Guliyev, Elif Sahin, Ebru Engin Delipoyraz, Ali Alkan, Okan Aydın, Nurullah Ilhan, Ozkan Alan, Sinem Akbas, Yaprak Cağlar, Ali Kaan Guren, Nadiye Sever, Halil Ibrahim Ellez, Fatih Selcukbiricik, Mustafa Muhammed Atcı, Ahmet Bilici, Nebi Serkan Demirci, Tugba Basoglu, Cengiz Karacin, Ismail Oguz Kara, Bulent Yıldız, Turkkan Evrensel, Mustafa Karaca, Omer Dizdar, Elif Atag, Alpaslan Ozgun, Osman Kostek

Source: Scientific Reports, Vol 15, Iss 1, Pp 1-8 (2025)

Subject Terms: Adjuvant therapy, Dabrafenib plus trametinib, Chemotherapy, Immune checkpoint inhibitors, Melanoma, Survival outcomes, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/9828f0522bfd4c938176e3ac69348cb2